Last reviewed · How we verify
mPnC candidate (mpnc-candidate)
The mPnC candidate (mpnc-candidate) from Pfizer Inc. is an investigational drug that has not yet received FDA approval. It is designed to target specific mechanisms in the body to treat certain diseases. The drug's mechanism of action involves a novel approach, and it is currently in clinical trials to evaluate its efficacy and safety. While no FDA label is available, early studies have shown promising results, but more data is needed to confirm its potential. The drug is being evaluated for several indications, and its safety profile is under close scrutiny.
At a glance
| Generic name | mpnc-candidate |
|---|---|
| Sponsor | Pfizer |
| Drug class | Novel therapeutic agent |
| Target | Specific protein or receptor involved in disease pathology |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | TBD |
Approved indications
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older
- Prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae in adults 18 years of age and older
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 50 years of age and older
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 65 years of age and older
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with certain underlying medical conditions
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with chronic heart disease, chronic lung disease, diabetes mellitus, or alcoholism
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with functional or anatomic asplenia
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cochlear implant
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with immunocompromising conditions
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and other conditions that increase the risk of invasive pneumococcal disease
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease and other conditions that increase the risk of invasive pneumococcal disease
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak and other conditions that increase the risk of invasive pneumococcal disease
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cochlear implant and other conditions that increase the risk of invasive pneumococcal disease
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease
- Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and cerebrospinal fluid leak
Pipeline indications
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Ibuprofen
- Pain medications
- Anticoagulants
- Antiplatelets
- Selective serotonin reuptake inhibitors (SSRIs)
- Serotonin-norepinephrine reuptake inhibitors (SNRIs)
- Tricyclic antidepressants
- Monoamine oxidase inhibitors (MAOIs)
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Corticosteroids
Key clinical trials
- A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |